Australia is famous, among other things, for venomous animals. Its plants, it turns out, are just as hostile. Now, researchers at the University of Queensland have isolated “neurotoxic peptides from the venom of the giant Australian stinging tree,” as they titled their paper. While the tree’s venomous effects were no secret – the authors wrote that it is known for its “remarkably persistent and painful stings upon contact,” which can produce pain flares for weeks – the effect had been attributed to small molecules.

BioWorld looks at translational medicine, including: Epigenetic resistance to PARP inhibitors; Arthritis is different disease with antibodies than without.

The European Society for Medical Oncology is slanted toward clinical medicine, and plenary sessions at the ESMO Virtual Congress 2020 featured phase III trials on approved drugs. But there were smaller sessions devoted to basic science as well. At one of those sessions, several researchers shared new insights into metastasis.

LONDON - Scenic Biotech BV has signed up Genentech as first partner for its high-throughput platform for identifying genetic modifiers that can suppress or even completely block the effect of a disease-causing mutated gene, as starting points for drug discovery and development. Under the terms of the agreement, Scenic will identify modifiers in undisclosed therapeutic areas, with Genentech, part of the Roche Group, having an option to take multiple targets into development.

Researchers at the University of California at San Diego have used RNA-targeted CRISPR to reverse symptoms in an animal model of myotonic dystrophy type 1 (DM1). They reported their findings in the Sept. 14, 2020, issue of Nature Biomedical Engineering.

BioWorld looks at translational medicine.